Company HedgePath Pharmaceuticals Inc

HedgePath Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapeutics for patients with certain cancers. The Company may also explore acquiring or licensing other therapeutics addressing unmet needs and orphan indications beyond cancer. The Company's preliminary focus is on the development of therapies for skin, lung and prostate cancers in the United States, with an indication targeting basal cell carcinoma (BCC) in patients with Basal Cell Carcinoma Nevus Syndrome (BCCNS, also known as Gorlin Syndrome). As of December 31, 2016, the Company was engaged in conducting an open label, Phase IIb clinical trial of a therapy for BCCNS. The Company's therapy is based upon super bioavailability (SUBA)-Itraconazole, an oral formulation of the marketed anti-fungal drug, itraconazole.